In 2023, David Sinclair's team at Harvard Medical School published an important result in <<The Journal of Clinical Endocrinology & Metabolism>>, The study focused on the effects of NMN (niacinamide mononucleotide) on body weight, cholesterol and blood pressure in overweight or obese adults.
The study recruited 30 overweight or obese adults over the age of 45. Participants were randomly divided into two groups, one taking NMN (1000mg each time) twice a day, and the other taking a placebo for 28 days. During the study, participants' weight, blood cholesterol levels and blood pressure were regularly measured.
Weight change:
Compared with participants who did not receive NMN, the NMN subjects lost more than 6 pounds (2.72 kg) in weight, suggesting that NMN supplementation can boost metabolic function and contribute to weight loss.
Cholesterol levels:
NMN is able to significantly reduce total blood cholesterol levels, including low-density lipoprotein (LDL) cholesterol, which is strongly associated with the buildup of blood vessel cholesterol. This finding supports the potential benefits of NMN for cardiovascular health.
Blood pressure changes:
The study also found that NMN was able to specifically reduce diastolic blood pressure (diastolic blood pressure is one of the key factors in hypertension), but had no significant effect on systolic blood pressure. This suggests that NMN supplementation may be a potential strategy to reduce high blood pressure in overweight and obese adults.
This study provides strong clinical evidence for the application of NMN in weight management and cardiovascular health maintenance.